Neuroprotection in outpatient treatment of post-covid syndrome
- 8 September 2025
- journal article
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 30 (3) , 53-60
Abstract
The aim of the study was to investigate the effectiveness of including cytoflavin in the complex outpatient therapy of patients with post-COVID syndrome. Materials and methods: the results of outpatient treatment of 106 patients (49 men and 57 women, average age 52.4 ± 5.2 years) with post-COVID syndrome were analyzed. In addition to standard clinical and laboratory observation, the HADS scale was used to assess the severity of anxiety and depression, and the general clinical impression — CGI-S. Spirometry, Stange, and Genchi tests were used to assess the state of the respiratory system. Patients were randomly divided into two groups comparable in gender and age. The examination was carried out before the start of treatment and after the end of the course of therapy (on the 30th day). In the main group (I, n = 56), in addition to standard drug therapy, psychotherapy, exercise therapy and vacuum therapy on the thoracic and lumbar spine, cytoflavin was prescribed: 20.0 ml intravenously by drip in 200 ml of 0.9% sodium chloride solution for 10 days, then 2 tablets 2 times a day for 20 days. Patients in the comparison group (II, n = 50) received 10.0 ml of placebo diluted in 200.0 ml of 0.9% sodium chloride solution daily by intravenous drip, followed by taking the tablet form of vitamin B12 1 tablet 1 time per day for 20 days. Results: the inclusion of cytoflavin contributed to a more pronounced positive dynamics of clinical indicators (“chest pain” — 6 times in Group 1 and 2.2 times in the comparison group, “headaches” — 7 and 3 times, respectively, and “tachycardia” — 5.2 and 3 times, respectively (p < 0.01). Spirometry also revealed a more pronounced positive dynamics of external respiration indicators: deeper and slower breathing, relatively high ventilation reserve indicators, a longer time during the Stange and Gench tests. Against this background, a decrease in the level of anxiety and depression (according to the HADS scale) was noted: the frequency of recording atypical depressive symptoms decreased according to the “anxiety” indicator by almost 9 times in the main group and only 2.5 times in the comparison group, according to the “clinical depression” indicator — 12.5 and 5.5 times, respectively (p < 0.01). As a result, the majority (90.9%) of patients who received in the therapy scheme cytoflavin, the treatment was recognized as effective (according to the CGI scale). Conclusion. Тhe results obtained, along with good tolerability of the drug, allow us to recommend its use in outpatient complex therapy of patients with post-covid syndrome.Keywords
This publication has 8 references indexed in Scilit:
- Asthenic post-COVID syndromeS.S. Korsakov Journal of Neurology and Psychiatry, 2023
- Combined effect of succinic acid, riboxin, nicotinamide, riboflavin for the treatment of chronic brain ischaemiaMeditsinskiy sovet = Medical Council, 2022
- Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic reviewKuban Scientific Medical Bulletin, 2021
- Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of CardiologyRussian Journal of Cardiology, 2021
- SARS-CoV-2 and the Brain: What Do We Know about the Causality of ‘Cognitive COVID?Journal of Clinical Medicine, 2021
- Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic TargetBiologics: Targets and Therapy, 2021
- Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and ManifestationsJournal of Molecular Neuroscience, 2021
- The landscape of cognitive function in recovered COVID-19 patientsJournal of Psychiatric Research, 2020